文献速递血栓与止血

胰腺癌临床试验中静脉血栓栓塞报告不一致:血栓预防与化疗试验的系统综述与荟萃分析

Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials.
PubMed 文献 · J Thromb Haemost · 2020-12-03

结论提示化疗试验中VTE被低估,需标准化监测与报告。

要点

  • 胰腺癌化疗试验报告的VTE发生率(5.9%)显著低于血栓预防试验(16.5%)。
  • 症状性VTE在化疗试验中报告率也显著低于血栓预防试验(5.4% vs 10.5%)。
  • 临床试验中VTE监测与报告标准不统一,可能导致发生率被低估。

核心结论

  • 胰腺癌化疗随机对照试验报告的VTE发生率显著低于血栓预防试验,提示化疗试验中VTE未被充分识别。

研究设计与样本

  • 系统检索MEDLINE、EMBASE和Clinicaltrials.gov,纳入随机对照试验进行荟萃分析。
  • 化疗试验为评估晚期胰腺癌化疗方案的随机对照试验且报告血栓为不良事件。
  • 血栓预防试验需报告非抗凝胰腺癌队列的血栓发生率。
  • 采用随机效应模型计算VTE和动脉血栓的合并事件率。

主要发现

  • 13项化疗研究(5694例)的VTE合并发生率为5.9%(95%CI 3.9-9.0%)。
  • 化疗研究的症状性VTE合并发生率为5.4%(95%CI 3.5%-8.3%)。

临床怎么用

  • 临床医生应意识到胰腺癌化疗试验中VTE报告率可能偏低,需主动监测VTE症状。
  • 在解读胰腺癌化疗试验的安全性数据时,应考虑VTE报告不足的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the frequency of venous thromboembolism (VTE) in pancreatic cancer, it is inconsistently reported as an adverse event in clinical trials. We hypothesized that reported rates of VTE in pancreatic cancer clinical trials are influenced by the objectives of the trial, with higher rates reported in thromboprophylaxis compared with chemotherapeutic trials. We performed a systematic review and meta-analysis of randomized, controlled trials (RCT) in pancreatic cancer to quantify differences in reported rates of VTE in thromboprophylaxis and chemotherapeutic trials. METHODS: We systematically searched MEDLINE, EMBASE, and Clinicaltrials.gov. Eligible thromboprophylaxis RCTs were required to report rates of thrombosis in non-anticoagulant pancreatic cancer cohorts. Eligible chemotherapy studies were RCTs evaluating chemotherapy regimens in advanced pancreatic cancer and reported thrombosis as adverse events. Pooled event rates of VTE and arterial thrombosis were calculated using a random-effects model. RESULTS: The pooled VTE rate in 13 chemotherapy studies (5694 patients) was 5.9% (95% confidence interval [CI], 3.9-9.0%) compared with 16.5% (95% CI, 11.7%-23.3%; P < .001) in 9 thromboprophylaxis studies (631 patients). The pooled symptomatic VTE rate from chemotherapy studies was 5.4% (95% CI, 3.5%-8.3%), which was significantly lower than the pooled rate from thromboprophylaxis studies of 10.5% (95% CI, 7.3%-14.9%; P = .02). CONCLUSION: The VTE incidence reported in chemotherapy RCTs in pancreatic cancer is significantly lower than reported in thromboprophylaxis studies. This finding highlights the underrecognition of VTE in chemotherapeutic trials and emphasizes the need to standardize approaches towards monitoring and reporting of VTE in clinical trials.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chiasakul T, Patell R, Maraveyas A, et al. Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. J Thromb Haemost. 2020. PMID: 33174368. doi:10.1111/jth.15175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。